| Literature DB >> 28123724 |
Keisaku Kondo1, Taiju Shimbo2, Keitaro Tanaka1, Masashi Yamamoto1, Yoshifumi Narumi2, Junji Okuda3, Kazuhisa Uchiyama1.
Abstract
The present study aimed to evaluate whether preoperative chemoradiotherapy (CRT) has any adverse effects on laparoscopic surgery (LS) for locally advanced low rectal cancer (LARC). The study was performed at the Osaka Medical College Hospital, and included patients who were operated on between July 2006 and December 2013. The short-term outcomes in 156 patients who underwent surgery for LARC following CRT were evaluated, of whom 152 underwent LS. Among the patients who were followed for >40 months, 77 patients (the CRT group) were compared with 39 patients who underwent LS without CRT (the surgery-alone group) for long-term outcomes. The total number of patients who received sphincter-preserving surgery was 74%. No positive longitudinal resection margins were identified, and only 1.3% had identifiable positive circumferential resection margins. The complication rate was 14%, and no serious complications occurred. There were no significant differences between the CRT and the surgery-alone groups in terms of the 5-year relapse-free survival rate (70.1 vs. 61.5%; P=0.81) or the 5-year overall survival rate (88.3 vs. 69.2%; P=0.06). However, the 5-year local recurrence-free survival rate was significantly improved in the CRT group patients (96.1 vs. 79.5%; P=0.009). In conclusion, our results have demonstrated that LS with preoperative CRT appears to be feasible and safe, and may have beneficial effects on local recurrence.Entities:
Keywords: laparoscopic surgery; long-term outcome; low rectal cancer; preoperative chemoradiotherapy; short-term outcome
Year: 2016 PMID: 28123724 PMCID: PMC5245121 DOI: 10.3892/mco.2016.1098
Source DB: PubMed Journal: Mol Clin Oncol ISSN: 2049-9450
Patient characteristics.
| Characteristics | Number of patients |
|---|---|
| Age in years (median/range) | 62 (35–80) |
| Gender | |
| Male | 107 (68.6%) |
| Female | 49 (31.4%) |
| Tumor size in cm (median/range) | 4.0 ( |
| Tumor histology | |
| Tub1/tub2 | 151 (96.8%) |
| Poor/muc/sig | 5 (3.2%) |
| Depth of invasion | |
| T3 | 151 (96.8%) |
| T4 | 5 (3.2%) |
| Tumor location | |
| 0–5.0 cm[ | 82 (52.5%) |
| 5.1–10.0 cm[ | 74 (47.5%) |
The tumor location is defined as the distance from the anal verge. Tub1, well-differentiated tubular adenocarcinoma; tub2, moderately-differentiated tubular adenocarcinoma; poor, poorly-differentiated adenocarcinoma; muc, mucinous adenocarcinoma; sig, Signet-ring cell carcinoma; T3, tumor invades through the muscular propria into the subserosa or into peritonealized pericolic or perirectal tissues; T4, tumor directly invades other organs or structures and/or invades the visceral peritoneum.
Comparison of patient characteristics in the two groups.
| Characteristics | Preoperative CRT group (n=77) | Surgery-alone group (n=39) | P-value |
|---|---|---|---|
| Age (years) | 62.05±10.23 | 62.46±9.18 | 0.83 |
| Gender (male/female) | 72/27 | 27/12 | 0.64 |
| Tumor size (cm) | 4.02±0.14 | 4.02±0.20 | 1.00 |
| Tumor distance from the anal verge (cm) | 4.13±2.03 | 5.61±2.45 | <0.01 |
| Tumor histology (tub1/tub2/others) | 26/49/2 | 22/17/0 | 0.09 |
| cStage (II/IIIa/IIIb) | 13/42/22 | 11/20/8 | 0.32 |
Tub1, well-differentiated tubular adenocarcinoma; tub2, moderately-differentiated tubular adenocarcinoma; cStage, clinical stage.
Figure 1.Placement of the five laparoscopy ports. For stapler insertion, placement of the lower-right quadrant port is essential for successful transection of the rectum. The stapler should be inserted as caudally as possible. The numbers in the Figure indicate the size of the ports (in mm).
Surgical data.
| Operative procedure | Number of patients (%) |
|---|---|
| Laparoscopic surgery | 152 (97.4) |
| Low anterior resection/super-low anterior resection | 101 (64.7) |
| Intersphincteric resection | 24 (15.4) |
| Abdominoperineal resection | 27 (17.3) |
| Open surgery | 4 (2.6) |
| Abdominoperineal resection | 3 (1.9) |
| Total pelvic exenteration | 1 (0.6) |
Histological data following surgery.
| Type of surgery | Number of patients (%) |
|---|---|
| Circumferential resection margin | |
| Positive | 2 (1.3) |
| Negative | 154 (98.7) |
| Distal resection margin | |
| Positive | 0 (0) |
| Negative | 156 (100) |
Histological assessments of response to preoperative chemoradiotherapy.
| Response to NACRT | Number of patients (%) |
|---|---|
| Grade | |
| 0 | 0 (0) |
| 1a | 49 (31.4) |
| 1b | 32 (20.5) |
| 2 | 46 (29.5) |
| 3 | 29 (18.6) |
Histological criteria for assessment of response to neoadjuvant therapy were based on the Japanese classification of Colorectal Carcinoma, Second English Edition (6). NACRT, neoadjuvant chemoradiotherapy.
Postoperative mortality and morbidity.
| Characteristic | Number of patients (%) |
|---|---|
| Postoperative complication | 22 (14.1) |
| Anastomotic leakage | 4 (2.6) |
| Wound infection | 9 (5.8) |
| Ileus | 3 (1.9) |
| Pelvic abscess | 3 (1.9) |
| Urinary disorder | 3 (1.9) |
| Mortality | 0 (0) |
Figure 2.Five-year relapse-free survival rates in the two groups over the follow-up period. No significant differences were observed in the survival rates between the two groups. NACRT, neoadjuvant chemoradiotherapy.
Figure 3.Five-year overall survival rates in the two groups. Survival rates between the two groups were not significantly different. NACRT, neoadjuvant chemoradiotherapy.
Figure 4.Five-year local recurrence-free survival rates in the two groups. Local recurrence-free survival rates in the preoperative chemoradiotherapy group was an improvement compared with that in the surgery-alone group. NACRT, neoadjuvant chemoradiotherapy.
First recurrence and/or metastasis following surgery.
| Characteristic | Preoperative CRT group (n=77) (%) | Surgeryalone group (n=39) (%) |
|---|---|---|
| Presence of recurrence/metastasis | 23 (29.9) | 15 (38.5) |
| Local recurrence | 4 (5.2) | 8 (20.5) |
| Lung metastasis | 13 (16.9) | 3 (7.7) |
| Liver metastasis | 2 (2.6) | 1 (2.6) |
| Lung and liver metastasis | 1 (1.3) | 0 (0) |
| Lymph node metastasis | 3 (3.9) | 1 (2.6) |
| Others | 0 (0) | 2 (5.1) |
CRT, chemoradiotherapy.